Intriguingly, however, CP has a strong link with the development of PDA, and around 5% of patients with CP develop pancreatic cancer [48], making it tempting to speculate that plasma Gal-1 detection would be a valuable tool for screening patients with CP to identify risk of possible tumor development. This evidence concerns the gene LGALS1 and familial pancreatic carcinoma.